A Modified Electrochemical Sensor Based on N,S-Doped Carbon Dots/Carbon Nanotube-Poly(Amidoamine) Dendrimer Hybrids for Imatinib Mesylate Determination. [PDF]
Biosensors (Basel), 2023 Imatinib mesylate, an anticancer drug, is prescribed to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. A hybrid nanocomposite of N,S-doped carbon dots/carbon nanotube-poly(amidoamine) dendrimer (N,S-CDs/CNTD) was successfully ...
Saleh Mohammadnia M +3 more
europepmc +2 more sources
Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects. [PDF]
Clin Transl Sci, 2022 For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Na JY +7 more
europepmc +2 more sources
Green biosynthesis of magnetic iron oxide nanoparticles using Mentha longifolia for imatinib mesylate delivery. [PDF]
IET Nanobiotechnol, 2022 In this work, the rapid, facile, and eco‐friendly green process was introduced in the preparation of β‐cyclodextrin/magnetic iron oxide nanoparticles by using the aqueous Mentha longifolia extracts of Mentha longifolia.
Naeimipour B +4 more
europepmc +2 more sources
Imatinib Mesylate and Gray Hair [PDF]
New England Journal of Medicine, 2002 To the Editor: The impressive effects of the tyrosine kinase inhibitor STI571 (imatinib mesylate) in chronic myeloid leukemia were confirmed in the large trial by Kantarjian et al. (Feb. 28 issue).1 We would like to report a new side effect of the drug.
Gabriel Étienne +2 more
openalex +3 more sources
Imatinib mesylate in chordoma [PDF]
Cancer, 2004 AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Paolo G. Casali +17 more
openalex +4 more sources
Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1. [PDF]
Clin Case Rep, 2020 Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.
Yasuda KI +4 more
europepmc +2 more sources
Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate. [PDF]
Pharmaceutics, 2019 The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6,
Karolewicz B +4 more
europepmc +2 more sources
Erythema following imatinib mesylate [PDF]
British Journal of Haematology, 2003 Edward Duncan, Kavita Raj, Ghulam Mufti
openalex +4 more sources
Periorbital edema secondary to imatinib mesylate
Clinical Ophthalmology, 2010 Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland +2 more
doaj +5 more sources
The teratogenic effects of imatinib mesylate on rat fetuses
Toxicology Reports, 2015 Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors.
M.M. El Gendy +3 more
doaj +3 more sources